Certolizumab (Intrexon)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCertolizumab (Intrexon)

Drug Alias NameLactococcus lactis expressing certolizumabLactococcus lactis secreting certolizumabAG-014

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsInflammatory Bowel Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesIntrexon Corporation

China Registration ClassN/A

Develop Information

Active CompaniesIntrexon Corporation

Inactive CompaniesN/A

Active IndicationsInflammatory Bowel Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A